Please login to the form below

Not currently logged in
Email:
Password:

BMS’ Dr Mike Burgees joins Turnstone Biologics

He joins the immuno-oncology group as its president of R&D

Turnstone Biologics, a North American clinical-stage immuno-oncology company, has appointed Dr Mike Burgees as its president of research and development, a role that will see him lead all functions in the R&D organisation, including preclinical and clinical development.

Dr Burgees has over 20 years’ experience in drug development, most recently as senior vice president, cardiovascular, fibrosis and immunoscience at Bristol-Myers Squibb (BMS).

He said: “Turnstone Biologics is uniquely positioned to deliver breakthrough viral-based immunotherapies for patients with cancer.

“I look forward to working closely with Turnstone’s experienced team and founders, who are driven by science and innovation, to bring these breakthrough medicines to patients.”

Prior to his time at BMS, Dr Burgees held several senior leadership positions at Roche, including acting global head of Roche Pharma Research and Early Development (pRED) and senior vice president and global head of oncology research and early development.

Sammy Farah, president and chief executive officer, Turnstone Biologics, said: “Mike is one of the most respected research and development leaders in the pharmaceutical industry, and has successfully led the global development and registration of several anti-cancer medicines.

“Mike’s oncology expertise will be instrumental in advancing the development of our next-generation viral immunotherapies and powerful immuno-oncology R&D capabilities.”

6th December 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...
BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....

Infographics